A randomized trial that aimed to evaluate clinical and immune responses to a multipeptide-preconditioned DC preparation in melanoma patients showed that the use of in vitro-generated DCs along with the administration of GM-CSF produced stronger T cell responses and more clinical tumor regressions compared to the standalone administration of dendritic cells [150]. Here, CSF2 is linked to melanoma.